Pharma BD Deal Intelligence
GSK's second ADC deal with Hansoh Pharma in two months: $185M upfront for HS-20093, a B7-H3 targeted ADC with up to $1.5B in milestones. The deal reflects GSK's aggressive pivot into antibody-drug conjugates, sourcing novel targets from Chinese biotech at a pace rivaling larger competitors.
GSK signs licence deal for Hansoh cancer drug HS-20093 B7-H3 ADC worldwide rights excluding China.
FDA granted Orphan Drug Designation to risvutatug rezetecan (GSK'227) for SCLC (10 Dec 2025) — the fifth regulatory designation for the B7-H3 ADC.
GSK's B7-H3-targeted ADC risvutatug rezetecan (Ris-Rez) granted Orphan Drug Designation for SCLC by Japan's MHLW (23 Mar 2026) — the sixth regulatory…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
GSK licensed HS-20093, a B7-H3 targeted ADC with topoisomerase inhibitor payload, from Hansoh Pharma. GSK paid $185M upfront with up to $1.525B in success-based milestones plus tiered royalties. GSK obtained exclusive worldwide rights excluding Greater China. This was GSK's second ADC deal with Hansoh in two months.
35K US cases/yr · $4.2B Global SCLC Market (2025E)
ES-SCLC is an aggressive neuroendocrine tumor with limited treatment options beyond chemo-IO. B7-H3 is overexpressed in SCLC. Risvutatug rezetecan received FDA BTD and Orphan Drug Designation, with global Phase III initiated August 2025.
SCLC treatment includes chemo-IO (Tecentriq/Imfinzi + chemo) in 1L and topotecan in 2L+. DLL3-targeting agents (AbbVie tarlatamab/Imdelltra) emerging. HS-20093 B7-H3 targeting with 63.6% ORR is differentiated.
1K US cases/yr · $350M Global Osteosarcoma Market (2025E)
Osteosarcoma is a rare aggressive bone cancer with extremely limited options in relapsed/refractory setting. GSK227 received FDA BTD for adults progressed on 2+ prior lines. Phase 2 ARTEMIS-002: 20% ORR, 86.7% DCR, 19.8-month median DOR.
No targeted therapies approved for relapsed osteosarcoma; standard of care is salvage chemotherapy. BTD designation reflects high unmet need.
GSK paid $185M upfront for worldwide ex-China rights to HS-20093 B7-H3-targeting ADC.
EMA granted Priority Medicines (PRIME) designation to HS-20093 / GSK'227 (risvutatug rezetecan) for relapsed extensive-stage small-cell lung cancer, backed by ARTEMIS-001 Phase I data.
GSK launched global Phase III for risvutatug rezetecan in ES-SCLC. FDA granted Breakthrough Therapy and Orphan Drug.
Japan's Ministry of Health, Labour and Welfare granted Orphan Drug Designation to risvutatug rezetecan for SCLC, the sixth regulatory designation across FDA (2 BTD + ODD), EMA (PRIME + ODD) and Japan. Confirms accelerating global regulatory momentum for the GSK-licensed B7-H3 ADC.
Phase III in SCLC underway. Multiple Phase II studies in sarcoma, NSCLC, head/neck. Strong regulatory designations.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. (this deal) | 2023 | $1.7B | 74 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
| GSK plc / Human Genome Sciences | 2012 | $3.6B | 70 |
← Browse all deals · How we score deals
More: 2023 deals · GSK plc deals · Oncology deals